Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Gender Differences In Wheelchair Marathon Performances - Oita Wheelchair Marathon From 1983 To 2011, Romuald Lepers, Paul J. Stapley, Beat Knechtle
Gender Differences In Wheelchair Marathon Performances - Oita Wheelchair Marathon From 1983 To 2011, Romuald Lepers, Paul J. Stapley, Beat Knechtle
Faculty of Health and Behavioural Sciences - Papers (Archive)
Background: The purpose of the study was (1) to examine the changes in participation and performance of males and females at the Oita International Wheelchair Marathon in Oita, Japan, between 1983 and 2011, and (2) to analyze the gender difference in the age of peak wheelchair marathon performance. Methods: Age and time performance data for all wheelchair athletes completing the Oita International Wheelchair Marathon from 1983 to 2011 were analyzed. Results: Mean annual number of finishers was 123 ± 43 for males and 6 ± 3 for females (5.0% ± 2.0% of all finishers), respectively. Mean age of overall finishers …
Examining Gender In Pharmaceutical Rhetoric Through A Cultural Studies Lens: A Case Study On The Gardasil Vaccine, Jennifer Fickley-Baker
Examining Gender In Pharmaceutical Rhetoric Through A Cultural Studies Lens: A Case Study On The Gardasil Vaccine, Jennifer Fickley-Baker
Electronic Theses and Dissertations
On June 8, 2006, Merck announced the debut of Gardasil, the world's first vaccine found successful in preventing human papillomavirus (HPV) infections, a sexually transmitted infection that is one of the main causes of certain cancers in men and women, including cervical, vulvar, penile and anal cancers. To promote the vaccine's release, Merck launched Gardasil's "One Less" advertising campaign that included television commercials, print ads and a consumerfocused website (www.Gardasil.com), each promoting the message that "you" could now be "one less woman" affected by cervical cancer ("One Less" campaign). The vaccine, tested and approved only for females age 9-26, was …